eFFECTOR Therapeutics GAAP EPS of $0.08

• eFFECTOR Therapeutics press release (NASDAQ:EFTR): Q1 GAAP EPS of $0.08.
• The company had cash and cash equivalents, and short-term investments totaling $45.7 million as of March 31, 2022, compared to $49.7 million in cash and cash equivalents as of December 31, 2021.